JORVEZA Market

Key Factors Driving JORVEZA Growth

1. First Approved Targeted Corticosteroid for EoE

• Jorveza is one of the first approved corticosteroid therapies specifically formulated for eosinophilic esophagitis (EoE), the chronic inflammatory condition of the esophagus characterized by eosinophil infiltration and swallowing difficulties. It received marketing authorization in the EU in 2018 and has been used as a key pharmacological option for adults with EoE.
• Regulatory recognition includes orphan drug designation, which can enhance development incentives, market exclusivity, and pricing leverage — all of which support commercial uptake in rare diseases like EoE.

2. Innovation in Delivery and Efficacy Outcomes

• The orodispersible tablet design ensures gradual dissolution in the mouth and esophagus, improving local budesonide contact time with inflamed tissue — a key driver of symptomatic relief and histologic remission in clinical trials.
• Pivotal studies reported that ~58% of patients treated with Jorveza achieved clinico-pathological remission after 6 weeks versus none on placebo, and about 74–75% remained symptomatically controlled over longer treatment durations, compared with ~4% on placebo in maintenance settings.

3. Growing EoE Treatment Market Landscape

• The overall eosinophilic esophagitis therapeutic market is expanding rapidly as awareness, diagnosis rates, and treatment options increase. Analysts project the global EoE market to grow at double-digit CAGRs (e.g., ~28% from 2023 to 2033), driven by increasing prevalence and new therapies entering the market.
• Corticosteroids (like budesonide formulations including Jorveza) are expected to continue dominating a large share of the market, with corticosteroids comprising nearly half of EoE treatment revenue segments given their established role and guideline recommendations.
• Other forecasts suggest the EoE market (7MM) could grow from around USD 1.8 billion in 2023 to over USD 9.2 billion by 2035 in some estimates, reflecting the increasing number of diagnosed patients seeking therapeutic interventions.

4. Role as a First-Line/Standard Option in Clinical Practice

• Before the approval of targeted biologics like Dupixent (dupilumab) for EoE, clinicians often used off-label topical steroids (e.g., budesonide or fluticasone) to manage inflammation. Jorveza’s specific indication helps shift this practice toward an evidence-based, approved formulation.
• Even with biologics entering the landscape, many gastroenterologists continue to prescribe topical treatments first due to cost, route of administration, and long clinical experience with steroids, maintaining Jorveza’s relevance in treatment pathways.

5. Competitive Pressures and Pipeline Dynamics

• The EoE market is evolving with new targeted biologics and novel small molecules, including anti-IL-4/13 and other immunomodulators that compete with topical steroids in moderate-to-severe patients.
• Emerging therapies may capture share in moderate and refractory patient segments, which could impact Jorveza’s share over time, but its established position in milder disease and cost-sensitive segments can sustain growth.

JORVEZA Recent Developments

·       In November 2023, the Australian Pharmaceutical Benefits Scheme (PBS) updated its prescribing criteria for Jorveza, making it easier for a broader range of clinicians (not just gastroenterologists) to prescribe the drug for EoE. This is expected to improve access for patients across Australia, especially in regional and public health settings.

“JORVEZA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of JORVEZA for approved indication like Eosinophilic oesophagitis; as well as potential indications like Graft-versus-host disease and Gastrointestinal disorders in the 7MM. A detailed picture of JORVEZA’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the JORVEZA for approved and potential indications. The JORVEZA market report provides insights about JORVEZA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current JORVEZA performance, future market assessments inclusive of the JORVEZA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of JORVEZA sales forecasts, along with factors driving its market.

JORVEZA Drug Summary

JORVEZA (budesonide) is an orodispersible tablet formulation of budesonide, a potent topical glucocorticoid, specifically designed for the treatment of eosinophilic esophagitis (EoE) in adults over 18 years, enabling targeted anti-inflammatory action in the esophagus through its mucoadhesive properties that prolong contact time with the esophageal mucosa while minimizing systemic absorption. Indicated for both induction (1 mg twice daily for 12-14 weeks, achieving up to 85% histologic remission with <6 eos/hpf) and maintenance of clinico-pathological remission (0.5 mg twice daily), it inhibits pro-inflammatory mediators like thymic stromal lymphopoietin, interleukin-13, and eotaxin-3, reducing eosinophilic infiltration, improving dysphagia symptoms, and preventing recurrent esophageal strictures. Administered by placing the tablet on the tongue to disintegrate without water, followed by swishing and swallowing, the white, round, biconvex tablets (0.5 mg or 1 mg strengths) contain excipients like mannitol, crospovidone, and silica; common side effects include esophageal/oral candidiasis (up to 20%), nausea, dysgeusia, and dry mouth, with rare systemic effects like adrenal suppression at high doses. Approved by EMA in 2018 and available in Europe, Australia, Canada, and other regions under Dr. Falk Pharma, it offers a steroid-sparing alternative for EoE patients unresponsive to proton pump inhibitors. The report provides JORVEZA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the JORVEZA Market Report

The report provides insights into:

• A comprehensive product overview including the JORVEZA MoA, description, dosage and administration, research and development activities in approved indications like Eosinophilic oesophagitis; as well as potential indications like Graft-versus-host disease and Gastrointestinal disorders.
• Elaborated details on JORVEZA regulatory milestones and other development activities have been provided in JORVEZA market report.
• The report also highlights JORVEZA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The JORVEZA market report also covers the patents information, generic entry and impact on cost cut.
• The JORVEZA market report contains current and forecasted JORVEZA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The JORVEZA market report also features the SWOT analysis with analyst views for JORVEZA in approved and potential indications.

Methodology

The JORVEZA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JORVEZA Analytical Perspective by DelveInsight

In-depth JORVEZA Market Assessment

This JORVEZA sales market forecast report provides a detailed market assessment of JORVEZA for approved indication like Eosinophilic oesophagitis; as well as potential indications like Graft-versus-host disease and Gastrointestinal disorders in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted JORVEZA sales data uptil 2034.

JORVEZA Clinical Assessment

The JORVEZA market report provides the clinical trials information of JORVEZA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

JORVEZA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

JORVEZA Market Potential & Revenue Forecast

• Projected market size for the JORVEZA and its key indications
• Estimated JORVEZA sales potential (JORVEZA peak sales forecasts)
• JORVEZA Pricing strategies and reimbursement landscape

JORVEZA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• JORVEZA Market positioning compared to existing treatments
• JORVEZA Strengths & weaknesses relative to competitors

JORVEZA Regulatory & Commercial Milestones

• JORVEZA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

JORVEZA Clinical Differentiation

• JORVEZA Efficacy & safety advantages over existing drugs
• JORVEZA Unique selling points
  

JORVEZA Market Report Highlights

• In the coming years, the JORVEZA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The JORVEZA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JORVEZA’s dominance.
• Other emerging products for Eosinophilic oesophagitis; as well as potential indications like Graft-versus-host disease and Gastrointestinal disorders are expected to give tough market competition to JORVEZA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JORVEZA in approved and potential indications.
• Analyse JORVEZA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted JORVEZA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of JORVEZA in approved and potential indications.

Key Questions Answered in the JORVEZA Market Report

• What is the class of therapy, route of administration and mechanism of action of JORVEZA? How strong is JORVEZA’s clinical and commercial performance?
• What is JORVEZA’s clinical trial status in each individual indications such as Eosinophilic oesophagitis; as well as potential indications like Graft-versus-host disease and Gastrointestinal disorders and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JORVEZA Manufacturers?
• What are the key designations that have been granted to JORVEZA for approved and potential indications? How are they going to impact JORVEZA’s penetration in various geographies?
• What is the current and forecasted JORVEZA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of JORVEZA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to JORVEZA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is JORVEZA? What is the duration of therapy and what are the geographical variations in cost per patient?